Table 3.
Multivariate analysis | Sub-group analysis | ||||||
---|---|---|---|---|---|---|---|
Variables | Crude OR (95% CI) | P-Value | Adjusted OR (95% CI) | P-Value | Variable | OR (95% CI) | P-Value |
CYP2D6 (n = 448) | |||||||
Age | 18–59 | ||||||
18–59 | Ref. | Ref. | Men | Ref. | |||
>=60 | 1.148 (0.918–1.436) | 0.228 | 1.119 (0.956–1.503) | 0.116 | Women | 1.119 (0.881–1.422) | 0.358 |
Sex | >=60 | ||||||
Men | Ref. | Ref. | Men | Ref. | |||
Women | 1.289 (1.044–1.592) | 0.018 | 1.319 (1.066–1.632) | 0.011 | Women | 2.159 (1.386–3.363) | 0.001 |
CYP2C19 (n = 490) | |||||||
Age | 18–59 | ||||||
18–59 | Ref. | Ref. | Men | Ref. | |||
>=60 | 1.606 (1.319–1.956) | 0.000002 | 1.640 (1.343–2.002) | 0.000001 | Women | 0.949 (0.754–1.195) | 0.659 |
Sex | >=60 | ||||||
Men | Ref. | Ref. | Men | Ref. | |||
Women | 1.064 (0.877–1.291) | 0.528 | 1.139 (0.936–1.385) | 0.194 | Women | 1.691 (1.184–2.416) | 0.004 |
CYP2C9 (n = 187) | |||||||
Age | 18–59 | ||||||
18–59 | Ref. | Ref. | Men | Ref. | |||
>=60 | 0.803 (0.546–1.181) | 0.265 | 0.841 (0.570–1.241) | 0.383 | Women | 1.316 (0.906–1.910) | 0.149 |
Sex | >=60 | ||||||
Men | Ref. | Ref. | Men | Ref. | |||
Women | 1.372 (0.986–1.910) | 0.061 | 1.345 (0.964–1.878) | 0.081 | Women | 1.466 (0.702–3.063) | 0.308 |
SD, Standard Deviation; DDI, drug-drug interaction; OR, Odds Ratio; CI, Confidence Interval.